Duquesne Family Office: Doubling Down on Precision Health and Hard Tech in 2026-Q1

The biggest adds are not timid. Duquesne is pressing winners and upping macro risk where it thinks the market is still behind the story.

• Natera (20.86%): Adding $110.4K to a position already up 148.5% vs cost is a loud statement that this is the core engine of the book, not a trade. Precision diagnostics is being treated as a secular platform, not a one-off call.
• YPF (5.09%): A 433.1% share increase and a $121.5K dollar add turns YPF into a top-five holding. Paired with a new $36.2K stake in ARGT, Duquesne is effectively underwriting an Argentina risk-on regime through both single-stock and ETF exposure.
• STMicroelectronics (3.07%): A 237.8% share ramp and $63.5K add shows a preference for diversified, volume semis over just the marquee AI names. STM and a new $60.7K Broadcom position together say “own the plumbing of AI and connectivity.”
• New tech stack: Fresh positions in Broadcom, Intel, Arm, Seagate, and Qnity Electronics round out a full-stack semiconductor and storage bet, while new stakes in Twilio, Cloudflare, Unity, and Jabil extend that into software and hardware manufacturing. The common thread is monetizing data and compute demand, not consumer eyeballs.
• New health bets: Caris Life Sciences, Revolution Medicines, Nuvation Bio, Belite Bio, Olema, Xenon, and Humana broaden the health care side from a single flagship into a portfolio of pipeline and managed-care exposures, with several names currently marked below cost, implying they were initiated into weakness rather than chased.

The sells this quarter are not random; they’re a systematic migration away from capital-heavy energy hardware and lower-quality growth to fund the barbell.

• Energy hardware winners: Woodward is cut by 64.2% (-$135.9K) and Bloom Energy by 81.6% (-$81.9K), both after triple-digit gains versus cost. This looks like classic Duquesne behavior: monetize expensive green industrials and redirect into areas where upside-to-risk is still asymmetric.
• Mature and generic health: Teva is slashed 59.5% (-$105.3K) even with an 82.5% gain vs cost, while Insmed, despite being a large 6.43% position, is trimmed 22.1% (-$53.6K). The message is clear: capital is moving from late-cycle or de-risked pharma into higher-beta, earlier-stage pipelines.
• Lower-quality consumer and rail: Coupang and Restaurant Brands are both cut by more than 60% in shares, freeing up over $133K combined. Wabtec is axed by 68.4% (-$51.3K), and airlines (United) plus smaller consumer plays like Daktronics are also reduced. Duquesne is giving up more cyclical, execution-sensitive consumer and transport exposure to concentrate in structural growth.
• High-flyer trims in tech: Lattice Semiconductor, a strong performer (up 85.9% vs cost), is trimmed 65.1% (-$55.9K). That capital reappears in broader semi and storage names, suggesting a valuation-aware rotation within the same structural theme rather than an exit from chips altogether.

The sector bars tell a clean story: Duquesne is re-rating the portfolio toward secular earnings power and away from cyclical beta. Health care rises from 40.74% to 42.5%, anchored by Natera but now diversified across diagnostics, specialty pharma, and managed care.

Technology’s jump from 11.45% to 18.08% is almost entirely semis and infrastructure software. New stakes in Broadcom, Intel, Arm, Seagate, and multiple software names replace a chunk of the prior, more concentrated chip exposure, while trims in Lattice and Taiwan Semi indicate internal rebalancing rather than backing away from AI.

On the other side, energy drops from 12.75% to 8.95% as Woodward and Bloom are cut aggressively, even as YPF is scaled up and Vista Energy appears as a new position. Consumer discretionary shrinks sharply from 12.91% to 7.41% as Coupang, Restaurant Brands, United, and Daktronics are de-emphasized. Industrials slide from 8.11% to 6.1%, while basic materials and consumer staples edge up through additions in metals (Southern Copper, Cleveland-Cliffs, Linde) and food (BBB Foods, JBS). Emerging markets and commodities via EWZ, ARGT, and GSG creep higher to 6.65%, hinting at a small macro hedge alongside the stock-picking.

Taken together, the book reads like a deliberate repositioning for a world where earnings growth comes from biology and bandwidth, not from marginal consumer demand. Duquesne is willing to accept more idiosyncratic drug-development and diagnostics risk in exchange for multi-year optionality, while backing that up with tangible AI infrastructure in semis and storage.

The trims in energy equipment, consumer internet, and rails suggest less appetite for stories that need a perfect macro backdrop to work. Instead, Duquesne is concentrating into businesses where unit economics are driven by technology and intellectual property, whether that’s a prenatal test, a next-gen oncology pipeline, or the chips and networks that move data.

The Argentina cluster around YPF and ARGT, plus small commodity and metals adds, show a residual belief that select emerging markets and hard assets can still provide upside or at least diversification. But the capital allocation hierarchy is clear: precision health first, AI plumbing second, everything else is a funding source. If the last three years’ strong compounded returns are any guide, this quarter’s rotation is less about playing defense after a -4.0% print and more about resetting the portfolio for the next leg of structural growth.